A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetes

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

    Malene Hornbak, The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., School of Pharmaceutical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, DenmarkKristine Højgaard Allin, The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., DenmarkMajken Linnemann Jensen, Steno Diabetes Center A/S, Gentofte, Denmark, DenmarkCathrine Juel Lau, Research Centre for Prevention and Health, Capital Region of Denmark, Glostrup Hospital, Glostrup, Denmark, Denmark
  • Daniel Witte
  • Marit Eika Jørgensen
  • Annelli Sandbæk
  • Torsten Lauritzen
  • Åsa Andersson, Steno Diabetes Center A/S, Gentofte, Denmark, Oluf Pedersen, Institute of Biomedical Science, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, DenmarkTorben Hansen, Section of Molecular Diabetes & Metabolism, Institute of Clinical Research & Institute of Molecular Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark, Denmark
Original languageEnglish
JournalPLOS ONE
Volume9
Issue number8
Pages (from-to)e104837
ISSN1932-6203
DOIs
Publication statusPublished - 26 Aug 2014

See relations at Aarhus University Citationformats

Projects

ID: 84749252